PPD to open early-stage clinical research unit in Las Vegas

PPD
PPD is opening a 24-bed early-stage clinical research unit in Las Vegas.

PPD is opening a 24-bed clinical research unit in Las Vegas in support of its early drug development services.

The CRO chose this new site because it offers logistical and geographic access to the populated West Coast, said Cindy Doerfler, VP of PPD’s Early Development Division.

The new facility is located about 10 miles away from the McCarran International Airport, near the St. Rose Dominican Hospitals, San Martin campus, which was named by the U.S. News & World Report as one of the Best Regional Hospitals in Las Vegas metropolitan area, with expertise in areas such as neurological, orthopedics and cardiovascular cares.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

With such geographic vicinity, PPD will be able to utilize the facility’s hospital-based services and medical expertise, Doerfler said. Besides the St. Rose Dominican campus, it is also close to several universities, including two medical schools, as well as six local research sites.

The new unit will add on to PPD’s capability in early-stage development services currently offered at its Austin, TX, unit. The 128,000-square-foot Austin clinic, one of the largest in the world, can carry out several studies simultaneously in healthy volunteers, but the Las Vegas unit can support clinical research in patients as well.

It will support first-in-human through proof-of-concept trials, offering various services ranging from nonclinical consulting to protocol writing, protocol optimization, project management, laboratory services, monitoring, medical writing, data management, biostatistics and clinical pharmacology, Doerfler added.

Elaine Watkins will act as the Las Vegas facility’s medical director. She has 25 years of clinical experience and 12 years of experience in more than 200 early-phase clinical trials, according to PPD’s official website.

The company is expecting to initiate the first studies at the new facility in the third quarter of 2017.

Last December, rumors resurfaced that the North Carolina-based CRO was up for sale for about $5 billion, as the company enlisted Goldman Sachs, J.P. Morgan Chase and Centerview Partners to help it find a buyer.

Suggested Articles

Matching the right patients to the right trials is a key piece of the recruitment puzzle. In oncology, it can be life and death.

U.K.-based CRO Sygnature Discovery is buying up fellow native life science services provider XenoGesis in order to boost its preclinical offerings.

PRA Health is tapping Deep Lens and the Microsoft Azure platform in matchmaking cancer patients to the right trials to speed up recruitment.